Kymera Therapeutics (KYMR) PT Lowered to $69 at Morgan Stanley
- Microsoft (MSFT) Near Deal to Acquire Nuance (NUAN) - Report
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
Morgan Stanley analyst Vikram Purohit lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $69.00 (from $74.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Grupo Aeroportuario Del Sureste (ASR) to Sell
- FinecoBank (FBK:IM) PT Raised to EUR15.60 at Goldman Sachs
- Macquarie Downgrades Rengo Co Ltd. (3941:JP) to Neutral
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!